Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua F Apgar

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Molecular Biosystems|June 18, 2010
Sloppy models, parameter uncertainty, and the role of experimental designJoshua F Apgar, David K Witmer, Forest M White, et al.
Pharmaceutical Research|June 26, 2015
An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug ConjugatesJanice A Lansita, John M Burke, Joshua F Apgar, et al.
Plos Computational Biology|February 20, 2008
Stimulus design for model selection and validation in cell signalingJoshua F Apgar, Jared E Toettcher, Drew Endy, et al.
Mabs|March 23, 2023
Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questionsJoshuaine Grant, Fei Hua, Joshua F Apgar, et al.
Molecular Biosystems|November 14, 2012
Reply to Comment on "Sloppy models, parameter uncertainty, and the role of experimental design"David R Hagen, Joshua F Apgar, David K Witmer, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 30, 2023
Quantitative systems pharmacology model of GITR-mediated T cell dynamics in tumor microenvironmentYan Ji, Kumpal Madrasi, Deborah A Knee, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 29, 2019
Quantitative Systems Pharmacology Model of a Masked, Tumor-Activated AntibodyMark Stroh, Jason Sagert, John M Burke, et al.
Frontiers in Pharmacology|June 27, 2022
Early Feasibility Assessment: A Method for Accurately Predicting Biotherapeutic Dosing to Inform Early Drug Discovery DecisionsDiana H Marcantonio, Andrew Matteson, Marc Presler, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 15, 2023
A next generation mathematical model for the in vitro to clinical translation of T-cell engagersDavid Flowers, David Bassen, Georgi I Kapitanov, et al.
Current Opinion in Toxicology|January 9, 2018
Quantitative systems toxicologyPeter Bloomingdale, Conrad Housand, Joshua F Apgar, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Molecular Biosystems|June 18, 2010
Sloppy models, parameter uncertainty, and the role of experimental designJoshua F Apgar, David K Witmer, Forest M White, et al.
Pharmaceutical Research|June 26, 2015
An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug ConjugatesJanice A Lansita, John M Burke, Joshua F Apgar, et al.
Plos Computational Biology|February 20, 2008
Stimulus design for model selection and validation in cell signalingJoshua F Apgar, Jared E Toettcher, Drew Endy, et al.
Mabs|March 23, 2023
Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questionsJoshuaine Grant, Fei Hua, Joshua F Apgar, et al.
Molecular Biosystems|November 14, 2012
Reply to Comment on "Sloppy models, parameter uncertainty, and the role of experimental design"David R Hagen, Joshua F Apgar, David K Witmer, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 30, 2023
Quantitative systems pharmacology model of GITR-mediated T cell dynamics in tumor microenvironmentYan Ji, Kumpal Madrasi, Deborah A Knee, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 29, 2019
Quantitative Systems Pharmacology Model of a Masked, Tumor-Activated AntibodyMark Stroh, Jason Sagert, John M Burke, et al.
Frontiers in Pharmacology|June 27, 2022
Early Feasibility Assessment: A Method for Accurately Predicting Biotherapeutic Dosing to Inform Early Drug Discovery DecisionsDiana H Marcantonio, Andrew Matteson, Marc Presler, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 15, 2023
A next generation mathematical model for the in vitro to clinical translation of T-cell engagersDavid Flowers, David Bassen, Georgi I Kapitanov, et al.
Current Opinion in Toxicology|January 9, 2018
Quantitative systems toxicologyPeter Bloomingdale, Conrad Housand, Joshua F Apgar, et al.
Pageof 2